loading
Schlusskurs vom Vortag:
$1.63
Offen:
$1.71
24-Stunden-Volumen:
1.59M
Relative Volume:
0.67
Marktkapitalisierung:
$44.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.58M
KGV:
-0.3938
EPS:
-4.52
Netto-Cashflow:
$-42.82M
1W Leistung:
+30.88%
1M Leistung:
+58.93%
6M Leistung:
+26.24%
1J Leistung:
+4.09%
1-Tages-Spanne:
Value
$1.56
$1.80
1-Wochen-Bereich:
Value
$1.31
$1.80
52-Wochen-Spanne:
Value
$0.808
$2.50

Iterum Therapeutics Plc Stock (ITRM) Company Profile

Name
Firmenname
Iterum Therapeutics Plc
Name
Telefon
(872) 225-6077
Name
Adresse
FITZWILLIAM COURT, 1ST FLOOR, DUBLIN 2
Name
Mitarbeiter
14
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-14
Name
Neueste SEC-Einreichungen
Name
ITRM's Discussions on Twitter

Vergleichen Sie ITRM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
ITRM 1.78 44.85M 0 -35.58M -42.82M -4.52
VRTX 450.60 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.31 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.22 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.28 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.27 24.89B 3.30B -501.07M 1.03B 11.54

Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-05-28 Hochstufung Gabelli & Co Sell → Hold
2021-03-15 Hochstufung H.C. Wainwright Neutral → Buy
2020-06-02 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-01-21 Herabstufung Gabelli & Co Buy → Sell
2019-12-11 Herabstufung SVB Leerink Outperform → Mkt Perform
2019-06-21 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Iterum Therapeutics Plc Aktie (ITRM) Neueste Nachrichten

pulisher
08:49 AM

Iterum Therapeutics Regains Full Nasdaq Compliance - The Manila Times

08:49 AM
pulisher
Nov 15, 2024

Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

Iterum Therapeutics plc (ITRM) Quarterly 10-Q Report - Quartz

Nov 15, 2024
pulisher
Nov 15, 2024

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... - Yahoo Canada Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Iterum Therapeutics’ Strategic Advances with ORLYNVAH Approval - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Iterum Therapeutics PLC - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q3 Loss $-0.24 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

Iterum Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Iterum Therapeutics sees cash runway into 2025 - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Iterum Therapeutics reports Q3 non-GAAP EPS (24c) vs. ($1.20) last year - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Iterum's ORLYNVAH Gets FDA Nod; Q3 Shows $14.5M Cash Position Amid Wider Losses | ITRM Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Iterum Therapeutics (ITRM) Scheduled to Post Earnings on Thursday - Defense World

Nov 13, 2024
pulisher
Nov 11, 2024

Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - The Manila Times

Nov 11, 2024
pulisher
Nov 01, 2024

Iterum Therapeutics defers $20 million FDA milestone payment By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Iterum Therapeutics defers $20 million FDA milestone payment - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

Iterum Therapeutics : Financial Obligation Form 8 K - Marketscreener.com

Nov 01, 2024
pulisher
Nov 01, 2024

500: Something went wrong - Investing.com UK

Nov 01, 2024
pulisher
Oct 29, 2024

ITRMIterum Therapeutics plc Ordinary Share Latest Stock News & Market Updates - StockTitan

Oct 29, 2024
pulisher
Oct 29, 2024

FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract Infections - Contagionlive.com

Oct 29, 2024
pulisher
Oct 28, 2024

Iterum Scores First Approval For Oral Penem Antibiotic - Citeline

Oct 28, 2024
pulisher
Oct 28, 2024

Second Oral UTI Treatment Approved, But Still No Vaccine - Precision Vaccinations

Oct 28, 2024
pulisher
Oct 28, 2024

Biotech Alert: Searches spiking for these stocks today - TipRanks

Oct 28, 2024
pulisher
Oct 28, 2024

FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships - Benzinga

Oct 28, 2024
pulisher
Oct 28, 2024

FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment - Pharmaceutical Technology

Oct 28, 2024
pulisher
Oct 28, 2024

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - BioSpace

Oct 28, 2024
pulisher
Oct 28, 2024

NaoTrac to Redefine Surgical Navigation Robotics at MEDICA 2024 - Lelezard

Oct 28, 2024
pulisher
Oct 26, 2024

Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs - MSN

Oct 26, 2024
pulisher
Oct 26, 2024

Major Improvements In Iterum Therapeutics Plc (ITRM) Stock Need To Be Considered - Stocks Register

Oct 26, 2024
pulisher
Oct 26, 2024

Iterum Therapeutics (ITRM) Scores FDA Approval for New UTI Drug ORLYNVAH™ - BP Journal

Oct 26, 2024
pulisher
Oct 26, 2024

FDA approves new oral antibiotic ORLYNVAH for uUTIs By Investing.com - Investing.com Nigeria

Oct 26, 2024
pulisher
Oct 25, 2024

Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com

Oct 25, 2024
pulisher
Oct 25, 2024

Wall Street-Heavily Traded - WDRB

Oct 25, 2024
pulisher
Oct 25, 2024

Iterum Therapeutics Shares Soar on FDA's Orlynvah Approval - Marketscreener.com

Oct 25, 2024
pulisher
Oct 25, 2024

FDA approves new oral antibiotic ORLYNVAH for uUTIs - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

Iterum Therapeutics Gains FDA Approval for ORLYNVAH - TipRanks

Oct 25, 2024
pulisher
Oct 25, 2024

US FDA approves Iterum's treatment for urinary infection - Reuters.com

Oct 25, 2024
pulisher
Oct 25, 2024

Iterum Therapeutics announces FDA approval of Orlynvah - TipRanks

Oct 25, 2024
pulisher
Oct 25, 2024

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Manila Times

Oct 25, 2024
pulisher
Oct 20, 2024

Week Ahead (Jul.26-30): INFI To Provide Update On Eganelisib Trials, Writing's On The Wall For ITRM? - RTTNews

Oct 20, 2024
pulisher
Oct 15, 2024

Renaissance Technologies LLC Trims Stock Holdings in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World

Oct 15, 2024
pulisher
Oct 10, 2024

Iterum Therapeutics to Present Data at IDWeek 2024 - StockTitan

Oct 10, 2024
pulisher
Oct 10, 2024

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit - The Manila Times

Oct 10, 2024
pulisher
Oct 08, 2024

Iterum Therapeutics shareholders approve share issuance authority - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Iterum Therapeutics shareholders approve share issuance authority By Investing.com - Investing.com Canada

Oct 08, 2024
pulisher
Oct 04, 2024

Iterum Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Iterum Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com UK

Oct 04, 2024

Finanzdaten der Iterum Therapeutics Plc-Aktie (ITRM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):